NCT00383487 is a Phase 2 clinical trial of Calcitriol in Prostatic Neoplasms, sponsored by Stanford University.

Who is sponsoring NCT00383487?

NCT00383487 is sponsored by Stanford University.

What drugs are being tested in NCT00383487?

Interventions in NCT00383487: Calcitriol, Naproxen-n-butyl nitrate.

What condition does NCT00383487 study?

NCT00383487 studies Prostatic Neoplasms, Prostate Cancer.

Is NCT00383487 still recruiting?

NCT00383487 is currently terminated. Last updated 25 January 2013.

Last reviewed 2013-01-25 · How we verify

NCT00383487

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Terminated Phase 2 Last updated 25 January 2013

What this trial tests

Phase 2 trial testing Calcitriol in Prostatic Neoplasms in 20 participants. Terminated before completion.

Timeline

1 March 2005

Primary endpoint
1 July 2007

1 July 2007

Quick facts

Lead sponsor	Stanford University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 March 2005
Primary completion	1 July 2007
Estimated completion	1 July 2007
Sites	1 location across United States

Drugs / interventions tested

Calcitriol (CALCITRIOL) — full drug profile →
Naproxen-n-butyl nitrate — full drug profile →

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Stanford University

Who can join

Adults 18 to 90, male only, with Prostatic Neoplasms or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

PSA response - 50% PSA decline, PSA progression, PSA response duration, progressive disease, time to PSA progression.

Sponsor's own description

To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer.
Tang Y, Li Q, Zhou Z, Bai H, et al · · 2024 · cited 8× · PMID 39497134 · DOI 10.1186/s12951-024-02929-z
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
Patrikidou A, Zilli T, Baciarello G, Terisse S, et al · · 2021 · cited 7× · PMID 34707693 · DOI 10.1177/17588359211051870

Verify or expand the search:

Other trials of Calcitriol

Trials testing the same drug.

NCT06261905 — Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System · Phase 1 · completed
NCT05415254 — Calcitriol Supplementation in COVID-19 Patients · NA · unknown
NCT04801303 — Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients · Phase 4 · completed
NCT05765617 — Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients · Phase 2 · completed
NCT04967469 — Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in · NA · completed

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00383487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 25 January 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00383487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing